These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35269729)

  • 21. Duloxetine in the treatment of elderly people with major depressive disorder.
    Del Casale A; Girardi P; Brugnoli R; Sani G; Di Pietro S; Brugnoli C; Caccia F; Angeletti G; Serata D; Rapinesi C; Tatarelli R; Kotzalidis GD
    Riv Psichiatr; 2012; 47(6):479-88. PubMed ID: 23160108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of human platelet activation and in vivo vascular thrombosis by columbianadin: regulation by integrin α
    Hou SM; Hsia CW; Tsai CL; Hsia CH; Jayakumar T; Velusamy M; Sheu JR
    J Biomed Sci; 2020 May; 27(1):60. PubMed ID: 32375785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tangeretin regulates platelet function through inhibition of phosphoinositide 3-kinase and cyclic nucleotide signaling.
    Vaiyapuri S; Ali MS; Moraes LA; Sage T; Lewis KR; Jones CI; Gibbins JM
    Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2740-9. PubMed ID: 24135020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ginsenoside-Rp3 inhibits platelet activation and thrombus formation by regulating MAPK and cyclic nucleotide signaling.
    Irfan M; Jeong D; Kwon HW; Shin JH; Park SJ; Kwak D; Kim TH; Lee DH; Park HJ; Rhee MH
    Vascul Pharmacol; 2018 Oct; 109():45-55. PubMed ID: 29890296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. VEGF plasma level variations in duloxetine-treated patients with major depression.
    Fornaro M; Rocchi G; Escelsior A; Contini P; Ghio M; Colicchio S; De Berardis D; Amore M; Fornaro P; Martino M
    J Affect Disord; 2013 Nov; 151(2):590-595. PubMed ID: 23871390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Duloxetine in the treatment of major psychiatric and neuropathic disorders.
    Müller N; Schennach R; Riedel M; Möller HJ
    Expert Rev Neurother; 2008 Apr; 8(4):527-36. PubMed ID: 18416656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Normal Platelet Integrin Function in Mice Lacking Hydrogen Peroxide-Induced Clone-5 (Hic-5).
    Popp M; Thielmann I; Nieswandt B; Stegner D
    PLoS One; 2015; 10(7):e0133429. PubMed ID: 26172113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Duloxetine versus other anti-depressive agents for depression.
    Cipriani A; Koesters M; Furukawa TA; Nosè M; Purgato M; Omori IM; Trespidi C; Barbui C
    Cochrane Database Syst Rev; 2012 Oct; 10():CD006533. PubMed ID: 23076926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apolipoprotein A-IV binds αIIbβ3 integrin and inhibits thrombosis.
    Xu XR; Wang Y; Adili R; Ju L; Spring CM; Jin JW; Yang H; Neves MAD; Chen P; Yang Y; Lei X; Chen Y; Gallant RC; Xu M; Zhang H; Song J; Ke P; Zhang D; Carrim N; Yu SY; Zhu G; She YM; Cyr T; Fu W; Liu G; Connelly PW; Rand ML; Adeli K; Freedman J; Lee JE; Tso P; Marchese P; Davidson WS; Jackson SP; Zhu C; Ruggeri ZM; Ni H
    Nat Commun; 2018 Sep; 9(1):3608. PubMed ID: 30190457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Duloxetine: a review of its use in the treatment of major depressive disorder.
    Frampton JE; Plosker GL
    CNS Drugs; 2007; 21(7):581-609. PubMed ID: 17579500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Li G; Wang X; Ma D
    Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Farnesoid X Receptor and Its Ligands Inhibit the Function of Platelets.
    Moraes LA; Unsworth AJ; Vaiyapuri S; Ali MS; Sasikumar P; Sage T; Flora GD; Bye AP; Kriek N; Dorchies E; Molendi-Coste O; Dombrowicz D; Staels B; Bishop-Bailey D; Gibbins JM
    Arterioscler Thromb Vasc Biol; 2016 Dec; 36(12):2324-2333. PubMed ID: 27758768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognition in major depressive disorder: a 'Systemically Important Functional Index' (SIFI).
    McIntyre RS; Lee Y
    Curr Opin Psychiatry; 2016 Jan; 29(1):48-55. PubMed ID: 26575300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.
    Detke MJ; Lu Y; Goldstein DJ; Hayes JR; Demitrack MA
    J Clin Psychiatry; 2002 Apr; 63(4):308-15. PubMed ID: 12000204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AMPK inhibition protects against arterial thrombosis while sparing hemostasis through differential modulation of platelet responses.
    Kulkarni PP; Sonkar VK; Gautam D; Dash D
    Thromb Res; 2020 Dec; 196():175-185. PubMed ID: 32890901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
    Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
    J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
    J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression.
    Detke MJ; Lu Y; Goldstein DJ; McNamara RK; Demitrack MA
    J Psychiatr Res; 2002; 36(6):383-90. PubMed ID: 12393307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of peripheral serotonin and norepinephrine in the gastroprotective effect against stress of duloxetine.
    Ding H; Gao Y; Wang Y; Yao K; Wang G; Zhang J
    Eur J Pharmacol; 2023 Feb; 941():175499. PubMed ID: 36627097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.